I

n a bid to blunt criticism of drug pricing, Alnylam Pharmaceuticals (ALNY) is going back to the future. The drug maker plans to limit any future price hikes on a widely anticipated rare-disease drug to the inflation rate, a step that no drug maker has voluntarily embraced in more than two decades.

“As we transition from being an innovative R&D-stage company to a commercial-stage company, we are launching a set of patient access principles,” Alnylam chief executive John Maraganore said. “We plan to grow through innovation, not through price increases. We’ll raise prices to match the Consumer Price Index, and that’s it. And otherwise, we’ll grow, as a company, through innovations.”

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Reply to ugo Cancel reply

Please enter your name.
Please enter a comment.

  • good to hear. Although, to be honest, once the system is in place RNA therapeutics are dirt cheap to produce. It is indeed one of the many potential theoretical advantages of the technology

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.

X